Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study

OBJECTIVE: This phase 2 study examined the efficacy and safety of tolvaptan, an aquaretic drug, in the treatment of ascites associated with cancer. METHODS: In the dose-escalation phase, oral tolvaptan was initiated at a dose of 3.75 mg/day, and the dose was increased daily to 7.5, 15 and 30 mg/day....

Descripción completa

Detalles Bibliográficos
Autores principales: Kudo, Toshihiro, Murai, Yoshiyuki, Kojima, Yoshitsugu, Uehara, Kenji, Satoh, Taroh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937426/
https://www.ncbi.nlm.nih.gov/pubmed/33173939
http://dx.doi.org/10.1093/jjco/hyaa196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937426/
https://www.ncbi.nlm.nih.gov/pubmed/33173939
http://dx.doi.org/10.1093/jjco/hyaa196

Ejemplares similares